Mitochondria function as the main providers of cellular energy in cells, where most cellular ATP is generated via oxidative phosphorylation reactions. The mitochondria are surrounded by a double membrane structure, and the inner membrane contains the necessary protein complexes of the electron transport chain (ETC) and ATP generation.
In cases of mitochondrial dysfunction, high-energy organs such as the brain, heart, and kidneys suffer from malfunction. Consequently, the scientific community’s focus has been on developing agents capable of protecting mitochondrial structure during experimental studies.
SS-31 (Elamipretide) is a man-made tetrapeptide of the sequence D-Arg-Dmt-Lys-Phe-NHâ‚‚ that has attracted considerable attention due to its ability to target mitochondria specifically. The principle of its mechanism is based on interactions with cardiolipin, an unusual phospholipid present in the inner mitochondrial membrane nearly exclusively.
Connection between Cardiolipin and Mitochondria
Cardiolipin is critical in the retention of a highly folded structure of the inner mitochondrial membrane called cristae and the arrangement of ETC subunits into supercomplexes. Under conditions of cellular stress, cardiolipin undergoes peroxidation, resulting in cristae deformation, disruption of the ETC organization, and ultimately mitochondrial malfunction.
SS-31 is characterized by an impressive property to accumulate in the inner mitochondrial membrane in much higher concentrations compared to the concentration of the molecule in the cell. This localization is associated with a specific interaction of SS-31 with cardiolipin.
Mechanism of Molecular Binding
The binding of SS-31 to the cardiolipin molecule depends on electrostatic and hydrophobic interactions:
- Electrostatic Attraction: At physiological pH, the net charge of SS-31 is +3. It causes electrostatic attraction to the anionic inner mitochondrial membrane containing cardiolipin molecules. Cationic amino acids D-Arginine and Lysine form direct electrostatic bonds with anionic phosphate head groups of cardiolipin.
- Hydrophobic Insertion: Aromatic amino acids 2′,6′-dimethyltyrosine (Dmt) and Phenylalanine embed into the hydrophobic core formed by acyl chains of the membrane bilayer.
Both electrostatic and hydrophobic interactions allow for the efficient binding of SS-31 to the cardiolipin. The dissociation constant (Kd) of SS-31 and cardiolipin was determined by fluorescence spectroscopy to be 1.87 ± 0.64 μM.
Downstream Effects on Mitochondrial Function
1. Electron Transport Chain and ATP production
SS-31 is known to preserve cardiolipin and mitochondrial cristae structure, which ensures efficient transport of electrons via the respiratory chain. The enhanced P/O ratio (a measure of oxidative phosphorylation efficiency) found in several experiments in aged and metabolically stressed tissue suggests that SS-31 may support coupled respiration. In addition to this, it allows us to say something about the ability to produce ATP by the mitochondria.
The mechanism of SS-31 was studied beyond simple cardiolipin binding. A study done at the University of Washington using cross-linking with mass spectrometry discovered the interaction of SS-31 with 12 proteins localized in the inner mitochondrial membrane. Eight of them are involved in complexes responsible for the production of ATP, and four of them are responsible for the metabolism of 2-oxoglutarate (regulator of the Krebs cycle).
2. Reduction of Reactive Oxygen Species
There are several ways that SS-31 can potentially decrease the production of reactive oxygen species in the mitochondria. For example, it inhibits the peroxidase activity of cytochrome c (cyt c) upon its association with oxidized cardiolipin, with an EC50 of 3.5 ± 0.03 μM. Such inhibition prevents the involvement of the electron transport chain in ROS overproduction.
Most significantly, SS-31 does not represent the conventional antioxidant approach because it does not act merely as an ROS scavenger inside the cell. This peptide acts at the level of its source, which is the ETC, thus decreasing ROS production and contributing to ATP synthesis.
3. Mitochondrial Structure Preservation
Studies show that SS-31 plays a vital role in the maintenance of the mitochondrial structure by maintaining the elongation of the mitochondrial tubular structure and preventing fragmentation during stress.
In preclinical animal studies conducted on ischemia, there have been reports of preservation of the mitochondrial structure and quick recovery of ATP production upon reperfusion with the help of SS-31.
It has been found to have minimal effect on the structure, respiration, ATP production, and ROS generation in the healthy young preclinical models. It exerts its effects under stress conditions, which makes it a useful agent to study the physiology of mitochondria in diseased states.
SS-31 vs Other Mitochondrial-Targeted Research Peptides
| Peptide | Primary Target | Key Mechanism | Main Research Focus | Cardiolipin Interaction | Typical Research Applications | Notable Advantage |
| SS-31 (Elamipretide) | Cardiolipin (inner mitochondrial membrane) | Stabilizes cardiolipin, reduces cytochrome c peroxidase activity, and supports electron transport chain organization | Mitochondrial biology, oxidative stress, bioenergetics | Strong and selective | Ischemia-reperfusion injury, Barth syndrome, heart failure, kidney injury, neurodegenerative disease models | Selectively associates with cardiolipin-rich mitochondrial membranes, supporting mitochondrial structure and reducing excessive mitochondrial ROS generation in experimental models |
| BPC-157 | Multiple molecular pathways (no single confirmed receptor) | Modulates angiogenesis, nitric oxide signaling, and cytoprotective pathways | Tissue repair, gastrointestinal biology, musculoskeletal research | None Reported | Tendon, ligament, muscle, gastrointestinal, and wound-healing models | Broad activity across multiple experimental injury models |
| TB-500 (Thymosin β4 fragment) | Multiple molecular pathways (no single confirmed receptor) | Promotes actin dynamics, cell migration, and tissue remodeling | Regenerative biology, wound repair, musculoskeletal research | None Reported | Muscle, tendon, ligament, corneal, and wound-healing models | Strong effects on cell migration and tissue remodeling |
| GHK–Cu | Copper-dependent signaling pathways and extracellular matrix | Modulates gene expression, collagen synthesis, extracellular matrix remodeling, and antioxidant responses | Skin biology, wound healing, tissue remodeling | No established direct interaction | Dermatology, tissue regeneration, hair research | Broad regulation of genes involved in tissue remodeling and extracellular matrix maintenance |
Clinical Research Context
FDA has approved SS-31 as the first treatment for Barth syndrome. Elamipretide has been tested in clinical research programs for primary mitochondrial myopathy, heart failure, and age-related macular degeneration, among others.
A 2025 review paper published in Biomedicine & Pharmacotherapy concluded that recent studies indicate SS-31-induced regulation of mitochondrial membrane electrostatic potential and cardiolipin-associated proteins in mitochondrial physiology.
Applications in Research
In the context of research, SS-31 is continually being studied in a wide variety of disciplines. The compound has been tested for its efficacy in laboratory models of cardiac and skeletal muscle myopathy, ocular disorders, ischemia-reperfusion injuries, and neurological disorders. There are ongoing studies to explore the role of SS-31 in altering the binding of α-synuclein to cell membranes in relation to Parkinson’s disease.
From preclinical trials, it seems that SS-31 can access central nervous tissue after systemic administration, but data from humans are currently not available.
Frequently Asked Questions
1. What is SS-31’s primary mode of action?
The peptide specifically interacts with cardiolipin, a phospholipid mainly present within the inner mitochondrial membrane. The interaction occurs via electrostatic forces (+3 net charge on SS-31) and hydrophobic anchoring of the peptide to the lipid layer through aromatic amino acids. This allows maintenance of mitochondrial membrane integrity, preservation of cristae architecture, and efficient functioning of the electron transport chain.
2. In what way does SS-31 differ from classical antioxidants?
While classic antioxidants neutralize free radicals in all locations inside cells, SS-31 acts directly on mitochondria, which generate ROS. The peptide interacts with cardiolipin, preserves electron transport chain architecture, minimizes electron leakage that results in ROS generation, and at the same time contributes to ATP synthesis in mitochondria.
3. With which proteins does SS-31 interact inside mitochondria?
The interaction of SS-31 with 12 proteins inside mitochondria, located in the inner membrane, has been determined using chemical cross-linking and mass spectrometry methods. 8 of them participate in ATP-producing complexes, and 4 in the metabolism of 2-oxoglutarate, an important controller of the Krebs cycle.
4. How does SS-31 influence normal mitochondria?
SS-31 has been found to cause negligible changes in mitochondrial structure, energy production, respiration, and ROS production in normal animals in several studies carried out in the laboratory.
5. What fields of research are investigating SS-31?
Studies in the laboratory have studied SS-31 in models of heart disease, skeletal muscle diseases, kidney disease, neurodegeneration, injury from ischemia-reperfusion, and mitochondrial aging. Clinical studies have also been carried out in Barth syndrome, primary mitochondrial myopathy, and age-related macular degeneration.
References
6. Original peer-reviewed study on SS-31 and α-synuclein membrane binding/aggregation.
